Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
12/13/2012Meridian Bioscience Successfully Completes Beta Trials for Two New illumigene® Tests
CINCINNATI--(BUSINESS WIRE)--Dec. 13, 2012-- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has successfully completed beta trials for two new illumigene molecular amplification tests. These assays are designed to specifically detect the DNA of Chlamydia trachomatis and Neisseria gonorrhoeae, respectively, from both swab and urine samples. For the first time, these two new assays will also incorporate Meridian Bioscience’s new... 
 Printer Friendly Version
12/4/2012Meridian Bioscience, Inc. Declares Regular Quarterly Dividend and Accelerates Payment Date to December 24, 2012
CINCINNATI--(BUSINESS WIRE)--Dec. 4, 2012-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announced that its Board of Directors today declared an accelerated cash dividend of $0.19 per share payable on December 24, 2012 to shareholders of record on December 14, 2012. The declaration and payment of this cash dividend is in lieu of the regular quarterly cash dividend that would have normally been paid in February 2013. The a... 
 Printer Friendly Version
11/28/2012SensiFAST™ Genotyping Kit Exceed the Limit
CINCINNATI--(BUSINESS WIRE)--Nov. 28, 2012-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the worldwide release of SensiFAST Genotyping Kit, which has been specifically developed for the important field of genotyping. Bioline’s SensiFAST Genotyping Kit has been developed for fast, precise, and highly reproducible genotyping of sequence variants, including loci with... 
 Printer Friendly Version
11/8/2012Meridian Bioscience Reports Fourth Quarter and Full-Year 2012 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2013 Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 8, 2012-- Meridian Bioscience, Inc.: GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported record fourth quarter and full-year fiscal 2012 net sales of $43.7 million and $173.5 million, respectively, increases of 6% and 9%, respectively, from the same periods of the prior fiscal year; reported record fourth quarter ... 
 Printer Friendly Version
9/17/2012Meridian Bioscience Receives FDA Clearance for New Molecular Test: illumigene® Group A Strep
CINCINNATI--(BUSINESS WIRE)--Sep. 17, 2012-- Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received FDA clearance for a new molecular diagnostic test for Group A Streptococcus on the illumigene® platform. Group A Streptococcus is a bacterium commonly found in the human throat or on skin and causes a wide variety of diseases in humans, the most common being acute pharyngitis or strep throat. Grou... 
 Printer Friendly Version
8/28/2012Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2013 and Reaffirms Fiscal 2012 Guidance
CINCINNATI--(BUSINESS WIRE)--Aug. 28, 2012-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company’s fiscal 2013 sales and earnings estimates. Based on the Company’s business planning and budgeting activities for the fiscal year ending September 30, 2013, management expects net sales to be in the range of $190 to $195 million and per share diluted earnings to be between $0.86 and $0.91. Th... 
 Printer Friendly Version
7/26/2012Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Revises Fiscal 2012 Guidance
CINCINNATI--(BUSINESS WIRE)--Jul. 26, 2012-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported fiscal 2012 third quarter and nine months net sales of $42.1 million and $129.8 million, respectively, increases of 5% and 10%, respectively, from the same periods of the prior fiscal year; reported third quart... 
 Printer Friendly Version
7/17/2012Meridian Bioscience, Inc. to Release Fiscal 2012 Third Quarter and Nine Months Operating Results on July 26
CINCINNATI--(BUSINESS WIRE)--Jul. 17, 2012-- Meridian Bioscience, Inc. (NASDAQ: VIVO) has scheduled the release of its fiscal 2012 third quarter and nine months operating results on Thursday, July 26 at approximately 7:15 a.m. (Eastern). Meridian Bioscience is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers ... 
 Printer Friendly Version
4/26/2012Meridian Bioscience Reports Record Second Quarter and First Six Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2012 Guidance
CINCINNATI, Apr 26, 2012 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported record fiscal 2012 second quarter and six months net sales of $47.4 million and $87.7 million, respectively, increases of 16% and 12%, respectively, from the same periods of the prior fiscal year; reported record second quarter operating income ... 
 Printer Friendly Version
4/12/2012Meridian Bioscience Awarded New Agreement with Premier Healthcare Alliance for Molecular Diagnostic Tests and Instruments for C. difficile and Group B Streptococcus
CINCINNATI, Apr 12, 2012 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced it has signed a new group purchasing agreement with the Premier healthcare alliance to offer illumigene(R) C. difficile and illumigene Group B Streptococcus to its members at specially negotiated pricing. Premier serves more than 2,500 U.S. hospitals and 81,000-plus other healthcare sites. This agreement allows Premier alliance facilities to implemen... 
 Printer Friendly Version
4/12/2012Meridian Bioscience, Inc. to Release Fiscal 2012 Second Quarter Financial Results on April 26
CINCINNATI, Apr 12, 2012 (BUSINESS WIRE) --Meridian Bioscience, Inc. (NASDAQ: VIVO) has scheduled the release of its 2012 second quarter financial results for Thursday, April 26 at approximately 7:45 a.m. (Eastern). ABOUT MERIDIAN BIOSCIENCE, INC. Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmace... 
 Printer Friendly Version
3/21/2012Bioline Receives Clearance from TGA for the Commercialization in Australia of the New Molecular Test illumigene(R) Group B Streptococcus
CINCINNATI, Mar 21, 2012 (BUSINESS WIRE) --Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), today announced that it has received clearance from the Therapeutic Goods Administration (TGA) for its illumigene Group B Streptococcus (GBS) test, the newest molecular product on the illumigene platform. The approval in Australia for the commercialization of illumigene GBS, comes on the heels of the recent FDA ... 
 Printer Friendly Version
3/21/2012Bioline Receives Clearance from TGA for the Commercialization in Australia of the New Molecular Test illumigene® Group B Streptococcus
CINCINNATI--(BUSINESS WIRE)--Mar. 21, 2012-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), today announced that it has received clearance from the Therapeutic Goods Administration (TGA) for its illumigene Group B Streptococcus (GBS) test, the newest molecular product on the illumigene platform. The approval in Australia for the commercialization of illumigene GBS, comes on the heels of the rece... 
 Printer Friendly Version
3/20/2012Bioline Celebrates 20 Years of Service to Life Science
CINCINNATI--(BUSINESS WIRE)--Mar. 20, 2012-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), was founded in London, UK in 1992 by Marco Calzavara, President of Meridian Bioscience Europe. Bioline is a leading manufacturer and distributor of PCR enzymes and molecular biology reagents providing complete solutions to researchers in universities, major research institutions, hospitals, biotech and ph... 
 Printer Friendly Version
2/27/2012Meridian Bioscience Receives FDA Clearance for New Legionella Test
CINCINNATI--(BUSINESS WIRE)--Feb. 27, 2012-- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for TRU Legionella™, a new rapid assay for detection of legionellosis. TRU Legionella is a rapid lateral flow device that provides optimized detection of Legionella pneumophila serogroup 1 that is most commonly associated with Legionnaire’s disease. Suspected infectio... 
 Printer Friendly Version
2/16/2012Bioline Introduces New SensiFAST™ HRM Kit for Gene Mutations and SNP Analysis
CINCINNATI--(BUSINESS WIRE)--Feb. 16, 2012-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the latest addition to its SensiFAST family real-time PCR products. SensiFAST HRM Kit facilitates High Resolution Melt (HRM) curve analysis, enabling amplification and discrimination of even the most challenging sequence differences (such as class 4 SNPs) without sequence preference.... 
 Printer Friendly Version
1/25/2012Meridian Bioscience Reports First Quarter 2012 Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2012 Guidance
CINCINNATI--(BUSINESS WIRE)--Jan. 25, 2012-- Meridian Bioscience, Inc. (NASDAQ: VIVO): GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today: reported first quarter net sales of $40.3 million, an increase of 8% from the same period of the prior fiscal year; reported first quarter operating income of $9.8 million, an increase of 8% over the same period of the prior fiscal year; reported first quarter net earnings of $6.6 million, or $0.16 per diluted shar... 
Download PDFPrinter Friendly Version
1/18/2012Bioline Introduces HyperPAGE II Broad Range Prestained Protein Marker
CINCINNATI--(BUSINESS WIRE)--Jan. 18, 2012-- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), is proud to announce the latest addition to its HyperPAGE range of prestained molecular weight protein markers. HyperPAGE II contains 9 highly purified protein bands from 10 to 250kDa prestained with different fluorescence dyes to facilitate easy identification and orientation whether performing protein ... 
 Printer Friendly Version